Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
78.78
+1.38 (1.78%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Haemonetics Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
| 1,334 | 1,361 | 1,309 | 1,169 | 993.2 | |
Revenue Growth | -1.97% | 3.96% | 12.01% | 17.67% | 14.10% |
Cost of Revenue | 546.44 | 611.87 | 617.51 | 553.56 | 487.69 |
Gross Profit | 787.59 | 748.96 | 691.55 | 615.1 | 505.5 |
Selling, General & Admin | 442.42 | 436.79 | 429.78 | 376.68 | 340.14 |
Depreciation & Amortization Expenses | 44 | 48.26 | 32.03 | 32.64 | 47.41 |
Research & Development | 59.77 | 62.72 | 54.44 | 50.13 | 46.8 |
Other Operating Expenses | 84.67 | -20.63 | 10.42 | -0.38 | -9.6 |
Total Operating Expenses | 630.85 | 527.14 | 526.67 | 459.06 | 424.75 |
Operating Income | 156.73 | 221.82 | 164.88 | 156.03 | 80.75 |
Total Non-Operating Income (Expense) | -28.7 | -9.75 | -13.02 | -14.63 | -17.12 |
Pretax Income | 128.03 | 212.07 | 151.87 | 141.4 | 63.63 |
Provision for Income Taxes | 30.72 | 44.39 | 34.31 | 26 | 20.25 |
Net Income | 97.31 | 167.68 | 117.56 | 115.4 | 43.38 |
Net Income to Common | 97.31 | 167.68 | 117.56 | 115.4 | 43.38 |
Net Income Growth | -41.97% | 42.63% | 1.87% | 166.05% | -45.42% |
Shares Outstanding (Basic) | 47 | 50 | 51 | 51 | 51 |
Shares Outstanding (Diluted) | 47 | 51 | 51 | 51 | 51 |
Shares Change | -6.65% | -1.30% | -0.04% | 0.13% | 0.12% |
EPS (Basic) | 2.06 | 3.33 | 2.32 | 2.27 | 0.85 |
EPS (Diluted) | 2.05 | 3.31 | 2.29 | 2.24 | 0.84 |
EPS Growth | -38.07% | 44.54% | 2.23% | 166.67% | -45.81% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Free Cash Flow | 260.44 | 142.45 | 143.63 | 81.73 | 75.75 |
Free Cash Flow Growth | 82.83% | -0.82% | 75.73% | 7.89% | 5.56% |
Free Cash Flow Per Share | 5.50 | 2.81 | 2.79 | 1.59 | 1.48 |
Gross Margin | 59.04% | 55.04% | 52.83% | 52.63% | 50.90% |
Operating Margin | 11.75% | 16.30% | 12.60% | 13.35% | 8.13% |
Profit Margin | 7.29% | 12.32% | 8.98% | 9.87% | 4.37% |
FCF Margin | 19.52% | 10.47% | 10.97% | 6.99% | 7.63% |
EBITDA | 268.45 | 337.4 | 262.1 | 249.34 | 178.5 |
EBITDA Margin | 20.12% | 24.79% | 20.02% | 21.34% | 17.97% |
EBIT | 156.73 | 221.82 | 164.88 | 156.03 | 80.75 |
EBIT Margin | 11.75% | 16.30% | 12.60% | 13.35% | 8.13% |
Effective Tax Rate | 24.00% | 20.93% | 22.59% | 18.39% | 31.83% |